Back to Search Start Over

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Authors :
John Hilton
Karen Gelmon
Philippe L. Bedard
Dongsheng Tu
Hong Xu
Anna V. Tinker
Rachel Goodwin
Scott A. Laurie
Derek Jonker
Aaron R. Hansen
Zachary W. Veitch
Daniel J. Renouf
Linda Hagerman
Hongbo Lui
Bingshu Chen
Deb Kellar
Irene Li
Sung-Eun Lee
Takako Kono
Brian Y. C. Cheng
Damian Yap
Daniel Lai
Sean Beatty
John Soong
Kathleen I. Pritchard
Isabel Soria-Bretones
Eric Chen
Harriet Feilotter
Moira Rushton
Lesley Seymour
Samuel Aparicio
David W. Cescon
Source :
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Publication Year :
2022
Publisher :
Nature Portfolio, 2022.

Abstract

G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.

Subjects

Subjects :
Science

Details

Language :
English
ISSN :
20411723
Volume :
13
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Nature Communications
Publication Type :
Academic Journal
Accession number :
edsdoj.095627571b4e258e1890f77d3d7597
Document Type :
article
Full Text :
https://doi.org/10.1038/s41467-022-31199-2